EMPULSE: Empagliflozin in Patients Hospitalized for Acute Heart Failure

EMPULSE assessed the effects of empagliflozin, an SGLT2 inhibitor, on patients hospitalized for acute heart failure (AHF). The study showed that empagliflozin significantly improved clinical outcomes, survival, and quality of life for patients hospitalized with AHF, regardless of baseline physical impairment, LVEF, and diabetes status.

Produced by: Dr. Ashish Correa, MD and Dr. Anu Lala, MD
Reviewed by: Dr. Teodora Donisan, Dr. Amit Goyal

CardioNerds Infographics

Explore our comprehensive collection of infographics, categorized by cardiovascular topics such as heart failure and transplantation, arrhythmias and electrophysiology, cardio-obstetrics, cardiovascular imaging, congenital heart disease, prevention, coronary artery disease, critical care, hypertension, pericardial disease, pulmonary hypertension, valvular heart disease, vascular disease, women’s cardiovascular health, diversity, inclusion, and more!

Feel free to download and share these visuals in presentations or on social media. Please use the infographics as provided—without altering or cropping out the creators’ credit.

For even more learning, explore the CardioNerds Tweetorial Page, featuring a curated collection of educational tweetorials!